AR126731A1 - Composiciones y métodos para tratar la mastitis - Google Patents

Composiciones y métodos para tratar la mastitis

Info

Publication number
AR126731A1
AR126731A1 ARP220102123A ARP220102123A AR126731A1 AR 126731 A1 AR126731 A1 AR 126731A1 AR P220102123 A ARP220102123 A AR P220102123A AR P220102123 A ARP220102123 A AR P220102123A AR 126731 A1 AR126731 A1 AR 126731A1
Authority
AR
Argentina
Prior art keywords
compositions
methods
treating mastitis
mastitis
treating
Prior art date
Application number
ARP220102123A
Other languages
English (en)
Inventor
Hilary Phelps
Brianna Joy Pomeroy Beam
Richard Andrew Ewin
Christopher A Zook
Michael Kuhn
Xi Zeng
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of AR126731A1 publication Critical patent/AR126731A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un método para tratar una mastitis en un sujeto, caracterizado porque comprende: administrar a dicho sujeto una cantidad eficaz de péptido catelicidina 2 (CATH2) o una variante de este, con lo cual se trata dicha mastitis en dicho sujeto.
ARP220102123A 2021-08-05 2022-08-05 Composiciones y métodos para tratar la mastitis AR126731A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163229699P 2021-08-05 2021-08-05

Publications (1)

Publication Number Publication Date
AR126731A1 true AR126731A1 (es) 2023-11-08

Family

ID=85156347

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102123A AR126731A1 (es) 2021-08-05 2022-08-05 Composiciones y métodos para tratar la mastitis

Country Status (3)

Country Link
EP (1) EP4380915A1 (es)
AR (1) AR126731A1 (es)
WO (1) WO2023015274A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2396345T3 (pl) * 2009-02-13 2017-06-30 Universiteit Utrecht Holding B.V. Peptydy przeciwdrobnoustrojowe na bazie CMAP27
WO2014078373A1 (en) * 2012-11-13 2014-05-22 Iogenetics, Llc Antimicrobial compositions
EP3140315B1 (en) * 2014-05-09 2024-07-24 Universiteit Utrecht Holding B.V. New cath2 derivatives
CN112839670A (zh) * 2018-07-20 2021-05-25 昆泰克有限公司 可摄取的制剂

Also Published As

Publication number Publication date
WO2023015274A1 (en) 2023-02-09
EP4380915A1 (en) 2024-06-12

Similar Documents

Publication Publication Date Title
CL2018003582A1 (es) Composiciones para modular la expresión de c9orf72 (divisional solicitud 201702567)
JOP20190146A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
MX2023013577A (es) Composiciones de bismuto-tiol y metodos de uso.
PH12019500242A1 (en) 9-aminomethyl minocycline compounds and uses thereof
CL2019002325A1 (es) Combinaciones farmacéuticas para tratar cáncer.
PE20200600A1 (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc
MX2020009496A (es) Metodo para tratar asma o enfermedad alergica.
MX2018014966A (es) Peptidos monolipidados resistentes a proteasas.
AR124639A1 (es) Composición para el tratamiento de una enfermedad vascular, la prevención de una enfermedad vascular, el tratamiento de la hipertensión, o la prevención de la hipertensión
AR126731A1 (es) Composiciones y métodos para tratar la mastitis
MX2022002541A (es) Agente bioestimulante para tratar plantas y/o semillas de plantas.
AR128257A1 (es) Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting
MY186286A (en) A pharmaceutical composition for improving or preventing progression of chronic kidney disease
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
ZA202101942B (en) Oral care compositions comprising n-alkyl-n-acylglucamines
AR122318A1 (es) Método para el tratamiento del cabello
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
EA202090535A1 (ru) Противомикробная композиция
WO2017214394A3 (en) Methods of treating bone loss
MX2023002625A (es) Composiciones y metodos para proporcionar beneficios para la salud en un animal.
PL427987A1 (pl) Sposób modyfikacji stężenia arsenu
EA202091824A1 (ru) Ингибиторы prc2
AR128051A1 (es) Inhibidores de parp1
MX2022007453A (es) Potenciacion de tratamiento contra helmintos.